Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation

American Journal of Hematology

Volumn 87, Issue 6, 2012, Pages 643-645

  Helbig, Grzegorz ^a   Soja, Anna ^a   Bartkowska Chrobok, Aleksandra ^a   Kyrcz Krzemień, Sławomira ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; HYDROXYUREA; IMATINIB; INTERFERON; MERCAPTOPURINE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CHRONIC EOSINOPHILIC LEUKEMIA NOT OTHERWISE SPECIFIED; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; FEMALE; FOLLOW UP; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LUNG INFILTRATE; LYMPHOBLASTOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY; SYMPTOM; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BONE MARROW; CHRONIC DISEASE; CLONE CELLS; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; RISK; TREATMENT FAILURE; YOUNG ADULT;

EID: 84861346705     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23193     Document Type: Letter

References (22)

1. Bain BJ, Gilliland DG, Vardiman JW, et al. Chronic eosinophilic leukemia, not otherwise specified. In: Swierdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: International Agency for Research on Cancer; 2008. pp 68-73.
2. Swierdlow S, Campo E, Harris NL, et al., editors. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: International Agency for Research on Cancer; 2008.
3. Simon HU, Rothenberg ME, Bochner B, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126: 45-49.
4. Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126: 179-181.
5. Klion AD. Eosinophilic Myeloproliferative Disorders. In: American Society of Hematology Education Program Book, 2011. pp. 257-263.
6. Cools J, De Angelo DJ, Gotlib A, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
7. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005; 114: 7-25.
8. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome-A phase II study. Br J Haematol 2008; 143: 707-715.
9. Helbig G, Moskwa A, Hus M, et al. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer Chemother Pharmacol 2011; 67: 967-969.
10. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179.
11. Viniou N, Yataganas X, Abazis D, et al. Hypereosinophilia associated with monosomy 7. Cancer Genet Cytogenet 1995; 80: 68-71.
12. Breems DA, van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
13. 1-negative eosinophilic leukaemia with trisomy 8: Case report and review of cytogenetic studies. Scand J Haematol 1997; 18: 413-420.
14. Needleman SW, Mane SM, Gutheil JC, et al. Hypereosinophilic syndromewith evolution to m+yeloproliferative disorder: Temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 1990; 4: 149-155.
15. Pardanani A, Reeder T, Porrata L, et al. Imatinib therapy for eosinophilic disorders. Blood 2002; 100: 800a.
16. Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138: 77-81.
17. Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 1990; 89: 91-93.
18. Yamada O, Kitahara K, Imamura K, et al. Clinical and cytogenetic remission induced by interferon-α in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998; 58: 137-141.
19. Basara N, Markova J, Schmetzer B, et al. Chronic eosinophilic leukemia: Successful treatment with an unrelated bone marrow transplantation. Leuk Lymph 1998; 32: 189-193.
20. Mitelman F. An international system for human cytogenetic nomenclature. Basel: S. Karger; 1995.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the Acute Leukemias French-American-British (FAB) Co-Operative Group. Br J Haematol 1976; 33: 451-458.
22. Borowitz MJ, Chan JKC. B lymphoblastic leukaemia/lymphoma not otherwise specified. In: Swierdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: International Agency for Research on Cancer; 2008. pp 168-170.